Clinical Report: Addressing Growth Hormone Deficiency in MIRAGE Syndrome

Background

MIRAGE syndrome is a rare genetic disorder characterized by severe growth restriction and other systemic manifestations due to mutations in the SAMD9 gene. The condition poses significant clinical challenges, particularly regarding growth hormone therapy, due to the associated risk of myelodysplastic syndrome and acute myeloid leukemia. Understanding the endocrine implications of MIRAGE syndrome is crucial for managing affected patients effectively.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

• MIRAGE syndrome is caused by heterozygous gain-of-function mutations in the SAMD9 gene.
• Growth restriction in MIRAGE syndrome can result from panhypopituitarism leading to GHD.
• The case study reports a significant improvement in growth velocity and height standard deviation score in a patient treated with rhGH over six years.
• Close collaboration with hematology/oncology teams is essential when considering rhGH therapy in MIRAGE syndrome patients.
• Systematic GH stimulation testing is recommended for MIRAGE patients with marked growth failure.

Clinical Implications

Clinicians should consider the potential for GHD in patients with MIRAGE syndrome who exhibit significant growth failure. Careful risk-benefit analysis and hematological monitoring are essential when contemplating rhGH therapy in this population.

Conclusion

This case highlights the potential for safe and effective growth hormone therapy in selected patients with MIRAGE syndrome, emphasizing the need for careful monitoring and interdisciplinary collaboration.

Related Resources & Content

1. Frontiers in Pediatrics, 2026 -- Case Report: Unveiling the enigma: a rare male neonatal case of MIRAGE syndrome with female external genital presentation and literature review
2. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Multimodal Approaches in the Precision Treatment of Acromegaly
3. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Bioactive IGF-I Levels in Pediatric Patients Undergoing Growth Hormone Treatment
4. Emerging phenotypes linked to variants in SAMD9 and MIRAGE syndrome - PMC
5. Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society - PubMed
6. The Journal of Clinical Endocrinology & Metabolism — Management Strategies for Pediatric Patients with Adrenal Insufficiency
7. Emerging phenotypes linked to variants in SAMD9 and MIRAGE syndrome - PMC
8. Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society - PubMed
9. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors—a review of research and clinical practice - PMC